Neurocrine Biosciences, Inc.
19 de nov., 19h35
- Abertura
- US$ 163,37
- Máxima
- US$ 163,48
- Mínima
- US$ 156,31
- Fechamento
- US$ 156,59
- Volume
- 1.458.282
Quanto teria rendido?
Simulação no período do gráficoConsidera só a variação do preço de fechamento no período, sem proventos, taxas ou Imposto de Renda. Rentabilidade passada não garante resultado futuro.
Indicadores do dia
- Abertura
- US$ 163,70
- Máxima
- US$ 163,70
- Mínima
- US$ 153,46
- Volume
- 920,8
Indicadores
Carregando indicadores.
Proventos
Carregando proventos.
Consenso
Este recurso faz parte do plano Plus.
A empresa
Sobre a empresa
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 2,500 full-time employees. The company is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). The company also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator॥ / (AMPA PAM) and others.
- País
- Estados Unidos da América
- CEO
- Kevin Gorman
- Consulta do cadastro
- 20/11/2026
- Setor
- Manufacturing
